587 related articles for article (PubMed ID: 22696419)
1. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
2. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Chou B; Halladay JS; Olivero AG; Rudewicz PJ; Tian Q; Wong S; Zhang X
Xenobiotica; 2011 Dec; 41(12):1088-99. PubMed ID: 21838594
[TBL] [Abstract][Full Text] [Related]
4. A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma.
Ding X; Li F; McKnight J; Schmidt C; Strooisma K; Shimizu H; Faber K; Ware JA; Dean B
J Pharm Biomed Anal; 2014 Nov; 100():150-156. PubMed ID: 25165011
[TBL] [Abstract][Full Text] [Related]
5. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
6. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Lee LB; Pang J; Plise EG; Zhang X
Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
11. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Wong H; Gould SE; Budha N; Darbonne WC; Kadel EE; La H; Alicke B; Halladay JS; Erickson R; Portera C; Tolcher AW; Infante JR; Mamounas M; Flygare JA; Hop CE; Fairbrother WJ
Drug Metab Dispos; 2013 Dec; 41(12):2104-13. PubMed ID: 24041744
[TBL] [Abstract][Full Text] [Related]
12. Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study.
Ding X; Salphati L; Kim A; Morinello E; Wong L; Pang J; Percey S; Meng M; Reuschel S; Dean B
Biomed Chromatogr; 2015 Aug; 29(8):1274-9. PubMed ID: 25677784
[TBL] [Abstract][Full Text] [Related]
13. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
[TBL] [Abstract][Full Text] [Related]
14. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
[TBL] [Abstract][Full Text] [Related]
15. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
[TBL] [Abstract][Full Text] [Related]
17. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
18. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Sutherlin DP; Bao L; Berry M; Castanedo G; Chuckowree I; Dotson J; Folks A; Friedman L; Goldsmith R; Gunzner J; Heffron T; Lesnick J; Lewis C; Mathieu S; Murray J; Nonomiya J; Pang J; Pegg N; Prior WW; Rouge L; Salphati L; Sampath D; Tian Q; Tsui V; Wan NC; Wang S; Wei B; Wiesmann C; Wu P; Zhu BY; Olivero A
J Med Chem; 2011 Nov; 54(21):7579-87. PubMed ID: 21981714
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
